Pfiz­er de­tails mR­NA flu vac­cine da­ta, but re­vis­es time­line

Pfiz­er’s mR­NA flu vac­cine met both pri­ma­ry end­points in the 18- to 64-year-old pop­u­la­tion in an on­go­ing Phase III tri­al, the com­pa­ny an­nounced on Tues­day morn­ing. How­ev­er, ex­ec­u­tives are no longer shoot­ing for a 2024 launch.

While Pfiz­er ini­tial­ly pegged a pos­si­ble 2024 launch for its stand­alone mR­NA flu vac­cine, that tim­ing has been pushed to “af­ter 2024.” Its next-gen­er­a­tion mR­NA flu and Covid-19 com­bi­na­tion vac­cine is ex­pect­ed to launch in 2025, CEO Al­bert Bourla said in pre­pared re­marks ahead of the com­pa­ny’s third-quar­ter earn­ings call.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER